HK1183015A1 - Sodium salt of 6-fluoro-3-hydroxy-2-pyrazine carboxamide 6--3--2- - Google Patents

Sodium salt of 6-fluoro-3-hydroxy-2-pyrazine carboxamide 6--3--2-

Info

Publication number
HK1183015A1
HK1183015A1 HK13110207.3A HK13110207A HK1183015A1 HK 1183015 A1 HK1183015 A1 HK 1183015A1 HK 13110207 A HK13110207 A HK 13110207A HK 1183015 A1 HK1183015 A1 HK 1183015A1
Authority
HK
Hong Kong
Prior art keywords
fluoro
hydroxy
sodium salt
pyrazine carboxamide
pyrazine
Prior art date
Application number
HK13110207.3A
Other languages
English (en)
Chinese (zh)
Inventor
高倉惠子
中松奈美香
竹島佐紀子
上原小百合
Original Assignee
富山化學工業株式會社
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 富山化學工業株式會社 filed Critical 富山化學工業株式會社
Publication of HK1183015A1 publication Critical patent/HK1183015A1/xx

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D241/00Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
    • C07D241/02Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings
    • C07D241/10Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
    • C07D241/14Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D241/24Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/14Antivirals for RNA viruses
    • A61P31/16Antivirals for RNA viruses for influenza or rhinoviruses
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07BGENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Virology (AREA)
  • Oncology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Communicable Diseases (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Pulmonology (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Cosmetics (AREA)
HK13110207.3A 2010-09-30 2013-09-02 Sodium salt of 6-fluoro-3-hydroxy-2-pyrazine carboxamide 6--3--2- HK1183015A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2010221682 2010-09-30
PCT/JP2011/072333 WO2012043700A1 (ja) 2010-09-30 2011-09-29 6-フルオロ-3-ヒドロキシ-2-ピラジンカルボキサミドのナトリウム塩

Publications (1)

Publication Number Publication Date
HK1183015A1 true HK1183015A1 (en) 2013-12-13

Family

ID=45893139

Family Applications (1)

Application Number Title Priority Date Filing Date
HK13110207.3A HK1183015A1 (en) 2010-09-30 2013-09-02 Sodium salt of 6-fluoro-3-hydroxy-2-pyrazine carboxamide 6--3--2-

Country Status (20)

Country Link
US (3) US20130274472A1 (hr)
EP (1) EP2623498B1 (hr)
JP (1) JPWO2012043700A1 (hr)
CN (1) CN103209966B (hr)
CY (1) CY1117041T1 (hr)
DK (1) DK2623498T3 (hr)
ES (1) ES2554630T3 (hr)
HK (1) HK1183015A1 (hr)
HR (1) HRP20151263T1 (hr)
HU (1) HUE026872T2 (hr)
MY (1) MY161429A (hr)
PH (1) PH12015501649B1 (hr)
PL (1) PL2623498T3 (hr)
PT (1) PT2623498E (hr)
RS (1) RS54408B1 (hr)
SG (1) SG189161A1 (hr)
SI (1) SI2623498T1 (hr)
SM (1) SMT201600072B (hr)
TW (1) TWI552998B (hr)
WO (1) WO2012043700A1 (hr)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8778398B2 (en) 2008-11-04 2014-07-15 Jazz Pharmaceuticals, Inc. Immediate release formulations and dosage forms of gamma-hydroxybutyrate
MX2012011022A (es) 2010-03-24 2013-02-26 Jazz Pharmaceuticals Inc Formas de dosis de liberacion controlada para substancias de farmaco de alta dosis, solubles en agua e higroscopicas.
DK2623497T3 (en) * 2010-09-30 2016-03-21 Toyama Chemical Co Ltd Meglumine salt of 6-fluoro-3-hydroxy-2-pyrazinecarboxamide
EP2937348B1 (en) * 2012-12-22 2021-09-08 Kbp Biosciences Pte. Ltd. Process for the preparation of a compound used as mineralocorticoid receptor antagonist
JP6487051B2 (ja) * 2014-12-30 2019-03-20 サムヤン バイオファーマシューティカルズ コーポレイションSamyang Biopharmaceuticals Corporation ポリマーナノ粒子の凍結乾燥物、及びその製造方法
US10398662B1 (en) 2015-02-18 2019-09-03 Jazz Pharma Ireland Limited GHB formulation and method for its manufacture
TW201808291A (zh) * 2016-06-30 2018-03-16 富山化學工業股份有限公司 冷凍乾燥製劑之製造方法
US11504347B1 (en) 2016-07-22 2022-11-22 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
US11986451B1 (en) 2016-07-22 2024-05-21 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
UY37341A (es) 2016-07-22 2017-11-30 Flamel Ireland Ltd Formulaciones de gamma-hidroxibutirato de liberación modificada con farmacocinética mejorada
US11602512B1 (en) 2016-07-22 2023-03-14 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
US11602513B1 (en) 2016-07-22 2023-03-14 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
US20180263936A1 (en) 2017-03-17 2018-09-20 Jazz Pharmaceuticals Ireland Limited Gamma-hydroxybutyrate compositions and their use for the treatment of disorders
US11679083B2 (en) * 2017-12-28 2023-06-20 Fujifilm Toyama Chemical Co., Ltd. Method for producing freeze-dried formulation
KR20210094513A (ko) 2018-11-19 2021-07-29 재즈 파마슈티칼즈 아일랜드 리미티드 알코올-내성 약물 제형
JP2022522270A (ja) 2019-03-01 2022-04-15 フラメル アイルランド リミテッド 食事摂取状態における改善された薬物動態を有するガンマ-ヒドロキシ酪酸塩組成物
CN111249229B (zh) * 2020-03-10 2023-05-02 北京阜康仁生物制药科技有限公司 一种稳定的法匹拉韦注射液及其制备方法
TR202017792A2 (tr) * 2020-11-06 2021-01-21 Aroma Ilac Sanayi Ltd Sti 6-floro-3-hidroksi-2-pirazinkarboksamid etken maddesi veya sodyum tuzunu içeren liyofilizasyon tekniğiyle üretilen yeni bir farmasötik kompozisyon
CN112574130B (zh) * 2020-12-11 2021-10-15 山东大学 一种法匹拉韦药物共晶及其制备方法和应用
CN112546234B (zh) * 2020-12-11 2021-10-15 山东大学 一种法匹拉韦药用结合物及在制备抗病毒药物制剂中的应用
EP4265253A1 (en) 2020-12-18 2023-10-25 FUJIFILM Toyama Chemical Co., Ltd. Pharmaceutical composition
JPWO2022131112A1 (hr) 2020-12-18 2022-06-23
WO2023033683A1 (ru) * 2021-09-06 2023-03-09 Общество С Ограниченной Ответственностью "Промомед Рус" Противовирусная фармацевтическая композиция, содержащая фавипиравир и аминокислоту
US11779557B1 (en) 2022-02-07 2023-10-10 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
US11583510B1 (en) 2022-02-07 2023-02-21 Flamel Ireland Limited Methods of administering gamma hydroxybutyrate formulations after a high-fat meal

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100435315B1 (ko) 1998-01-07 2004-06-10 메이지 세이카 가부시키가이샤 결정학적으로 안정된 비정질 세파로스포린 조성물과 그제조 방법
PT1112743E (pt) 1998-08-20 2008-01-14 Toyama Chemical Co Ltd Derivados heterocíclicos azotados de carboxamidas ou os seus sais como agentes antivirais
CN1239511C (zh) 2000-02-16 2006-02-01 富山化学工业株式会社 新的吡嗪衍生物或其盐、以及含有该衍生物或盐的药物组合物
KR101479083B1 (ko) * 2007-02-16 2015-01-07 토야마 케미칼 컴퍼니 리미티드 피라진 유도체를 함유하는 의약조성물 및 피라진 유도체를 조합하여 사용하는 방법
JP5174365B2 (ja) * 2007-03-23 2013-04-03 第一三共株式会社 キノロン含有凍結乾燥製剤の製造方法
JP2008231064A (ja) 2007-03-23 2008-10-02 Nippon Shokubai Co Ltd カルバゾイルアルキル(メタ)アクリレートの製造方法
BRPI0817305B1 (pt) * 2007-09-27 2021-10-19 Fujifilm Toyama Chemical Co., Ltd. Sal de dicicloexilamina, e, processo para produzir um sal de dicicloexilamina
DK2407166T3 (da) 2009-03-13 2013-10-07 Toyama Chemical Co Ltd Tablet og granuleret pulver indeholdende 6-fluor-3-hydroxy-2-pyrazin-carboxamid
DK2623497T3 (en) 2010-09-30 2016-03-21 Toyama Chemical Co Ltd Meglumine salt of 6-fluoro-3-hydroxy-2-pyrazinecarboxamide

Also Published As

Publication number Publication date
HRP20151263T1 (hr) 2015-12-18
DK2623498T3 (en) 2016-02-22
ES2554630T3 (es) 2015-12-22
PH12015501649A1 (en) 2015-10-05
EP2623498A1 (en) 2013-08-07
PL2623498T3 (pl) 2016-05-31
TWI552998B (zh) 2016-10-11
EP2623498A4 (en) 2014-03-26
SMT201600072B (it) 2016-04-29
US9096547B2 (en) 2015-08-04
WO2012043700A1 (ja) 2012-04-05
US20150038713A1 (en) 2015-02-05
PT2623498E (pt) 2016-02-02
CN103209966A (zh) 2013-07-17
MY161429A (en) 2017-04-14
CY1117041T1 (el) 2017-04-05
SG189161A1 (en) 2013-05-31
CN103209966B (zh) 2015-06-10
RS54408B1 (en) 2016-04-28
SI2623498T1 (sl) 2016-03-31
EP2623498B1 (en) 2015-11-18
JPWO2012043700A1 (ja) 2014-02-24
US20130274472A1 (en) 2013-10-17
HUE026872T2 (en) 2016-07-28
US20150266831A1 (en) 2015-09-24
PH12015501649B1 (en) 2015-10-05
TW201219375A (en) 2012-05-16

Similar Documents

Publication Publication Date Title
HK1183015A1 (en) Sodium salt of 6-fluoro-3-hydroxy-2-pyrazine carboxamide 6--3--2-
HK1183014A1 (en) Meglumine salt of 6-fluoro-3-hydroxy-2-pyrazine carboxamide 6--3--2-
HK1252424A1 (zh) 鈉葡萄糖協同轉運蛋白1的抑制劑
PL2742051T3 (pl) Amorficzna postać soli sodowej dolutegrawiru
IL237581B (en) Derivatives of 6-oxo-pyrazinopyrrolopyrimidines
IL232599A (en) Hydrobromide salt of peridofidine
ZA201308086B (en) Derivatives of 1-anino-2-cyclopropylboronic acid
ZA201209407B (en) Modification of xylan
PT2539136T (pt) Poste de barreira e método de fabrico do mesmo
ZA201302476B (en) Aluminum salt containing high percentage of al30
AP3268A (en) Co-crystals and salts of CCR3-inhibitors
HK1210776A1 (en) Substituted sodium 1h-pyrazol-5-olate 1h--5-
GB0906379D0 (en) Reduced sodium salt
EP2922413A4 (en) SODIUM SODIUM COMPOSITIONS AND METHOD OF MANUFACTURE AND USE THEREOF
ZA201205320B (en) Preparation process of the sodium salt of esomeprazole
PT2542591T (pt) Derivados silílicos de polissacáridos
EP2688426A4 (en) SALT COMPOSITION WITH REDUCED SODIUM CONTENT
PL2513060T3 (pl) Krystaliczna postać α karbabenzopirydu
IL243319A0 (en) Intermediates of teroarylpiperidine and piperazine derivatives
GB2493855B8 (en) Reduced sodium salt
HUP1000616A2 (en) Process for preparation of rosuvastatin salt
HU1000688D0 (en) Use of trifluoro-phal
GB201216287D0 (en) Reduced sodium salt